Servier’s ASCO 2025 Data: Advancing IDH-Mutated Cancer Treat...

At ASCO 2025, Servier’s Becky Martin discusses IDH-mutated cancers, including key insights on Tibsovo & Voranigo, and the implications for patients.

Live from ASCO 2025: Boehringer Ingelheim on unmet needs and...

Patient-focused manufacturing models for personalised therap...

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Jason Bock, co-founder and CEO of CTMC, a first-of-its-kind cell therapy engine.

CAR-T therapies: Faster, better, cheaper

In a new pharmaphorum podcast, editor-in-chief Jonah Comstock speaks with Phil Johnson, MD, president and CEO of Interius Biotherapeutics.

Oncology today: EVERSANA and pharmaphorum at ESMO 2024

The ESMO congress always disseminates the latest results of cancer research, a vibrant gathering and sharing of the latest data, communicating the next promising steps in oncological scient

Move over CAR-T: The potential of NK cells in cell therapy

The early successors in cell therapy have mostly been CAR-T therapies, with the T standing for T cells. But T cells aren't the only option for cell th